The Flow has not summarised this story yet — read it at arXiv Computation and Language.
arXiv:2609.01202v1 Announce Type: cross Abstract: Clinical trials are essential for advancing cancer care and drug development, but many fail because of insufficient patient enrollment. While there i...
ClinicalReTrial is a multi‑agent AI system that treats clinical trial protocol optimization as an iterative redesign problem on textual documents. It combines failure diagnosis, safety‑aware modifications, and candidate evaluation within a closed‑loop, reward‑driven framework, using a predictive model as a simulation environment for low‑cost, dense feedback. The system achieves a 56.7% conversion of failed protocols to predicted successes, with a 7.4% average success probability increase at a negligible cost, and its redesign patterns align with real‑world expert changes.
arXiv:2606. 19245v1 Announce Type: new Abstract: Artificial intelligence (AI) agents promise to accelerate drug discovery by compressing interpretation and decision-making loops, but practical deployment requires trusted evaluation on realistic program decisions.
arXiv:2412.09378v4 Announce Type: replace-cross Abstract: Clinical trials bridge basic research and clinical application, serving as essential steps in drug development. This review examines clinical...
GxP-Agent is a multi‑agent system that transforms clinical trial protocols into CDISC‑compliant datasets by encoding the regulatory workflow as a directed acyclic graph (DAG). Each node in the DAG represents a domain‑specific task executed by a worker agent with specialized skill context, validation gates, and conditional retry logic. On the CDISC‑Bench benchmark, GxP-Agent with Claude Sonnet 4.6 achieved a perfect 100 % structural match for 49 variables across 254 records, outperforming single‑agent and flat multi‑agent baselines and enabling weaker models like GPT‑4.1 to reach 59.2 % under the same DAG.
arXiv:2606. 28692v1 Announce Type: new Abstract: Treatment reasoning underpins every therapeutic decision, integrating disease context, comorbidities, medications, contraindications, and evolving biomedical knowledge to select an appropriate therapy.